{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T12:32:31Z","timestamp":1777984351131,"version":"3.51.4"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:00:00Z","timestamp":1773446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Allergy Asthma Clin Immunol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Organizing pneumonia (OP) is a rare interstitial lung disease characterized by intra-alveolar fibroblastic plugs and chronic inflammation. Although most cases are idiopathic, OP may occur secondary to infections, autoimmune disease, or drug exposure. Pulmonary complications of tumor necrosis factor-alpha (TNF-\u03b1) inhibitors are uncommon, and infliximab-associated OP has not yet been described in the pediatric population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 12-year-old girl with ulcerative colitis (UC) on infliximab presented with three weeks of dyspnea, fever, and pleuritic chest pain. Computed tomography (CT) revealed bilateral peripheral infiltrates. Microbiologic testing and bronchoalveolar lavage were negative. Wedge biopsy demonstrated fibroblastic plugs (Masson bodies), consistent with OP. Infliximab was discontinued. The patient\u2019s symptoms improved without corticosteroids, with near-complete radiologic resolution at 2 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This case highlights probable infliximab-associated OP in a pediatric patient, highlighting a need for awareness of rare pulmonary toxicities from biologics. Importantly, resolution occurred without corticosteroids, suggesting that withdrawal of the offending agent may suffice in select cases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13223-026-01022-4","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T10:14:10Z","timestamp":1773483250000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Organizing pneumonia potentially caused by infliximab in a pediatric patient with ulcerative colitis"],"prefix":"10.1186","volume":"22","author":[{"given":"Brian","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isaac","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Bax","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samira","family":"Jeimy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,14]]},"reference":[{"issue":"10","key":"1022_CR1","doi-asserted-by":"publisher","first-page":"356","DOI":"10.3390\/jcm7100356","volume":"7","author":"S Skeoch","year":"2018","unstructured":"Skeoch S, Weatherley N, Swift AJ, Oldroyd A, Johns C, Hayton C, et al. Drug-induced interstitial lung disease: a systematic review. J Clin Med. 2018;7(10):356. PMID: 30326612.","journal-title":"J Clin Med"},{"issue":"2","key":"1022_CR2","first-page":"e20240110","volume":"50","author":"GDP Bridi","year":"2024","unstructured":"Bridi GDP, Fonseca EKUN, Kairalla RA, Amaral AF, Baldi BG. Drug-induced lung disease: a narrative review. J Bras Pneumol. 2024;50(2):e20240110. PMID: 39356911.","journal-title":"J Bras Pneumol"},{"key":"1022_CR3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1465-9921-13-39","volume":"13","author":"O Matsuno","year":"2012","unstructured":"Matsuno O. Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches. Respir Res. 2012;13:39. PMID: 22682385.","journal-title":"Respir Res"},{"key":"1022_CR4","first-page":"85","volume":"15","author":"AJ Hayek","year":"2015","unstructured":"Hayek AJ, Pfanner TP, White HD. Inflammatory bowel disease of the lung: the role of infliximab? Respir Med Case Rep. 2015;15:85\u20138.","journal-title":"Respir Med Case Rep"},{"issue":"6","key":"1022_CR5","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1517\/14740338.2016.1160053","volume":"15","author":"D Patel","year":"2016","unstructured":"Patel D, Madani S, Patel S, Guglani L. Review of pulmonary adverse effects of infliximab therapy in Crohn\u2019s disease. Exp Opin Drug Saf. 2016;15(6):769\u201375.","journal-title":"Exp Opin Drug Saf"},{"issue":"1","key":"1022_CR6","doi-asserted-by":"publisher","first-page":"200269","DOI":"10.1183\/20734735.0269-2020","volume":"17","author":"A Jochmann","year":"2021","unstructured":"Jochmann A, Trachsel D, Hammer J. Inflammatory bowel disease and the lung in paediatric patients. Breathe. 2021;17(1):200269\u20139.","journal-title":"Breathe"},{"issue":"7","key":"1022_CR7","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.rmed.2012.03.005","volume":"106","author":"J Peradzy\u0144ska","year":"2012","unstructured":"Peradzy\u0144ska J, Krenke K, Lange J, Banaszkiewicz A, \u0141azowska-Przeorek I, Radzikowski A, et al. Low prevalence of pulmonary involvement in children with inflammatory bowel disease. Respir Med. 2012;106(7):1048\u201354.","journal-title":"Respir Med"},{"issue":"37","key":"1022_CR8","doi-asserted-by":"publisher","first-page":"13501","DOI":"10.3748\/wjg.v20.i37.13501","volume":"20","author":"XQ Ji","year":"2014","unstructured":"Ji XQ, Wang LX, Lu DG. Pulmonary manifestations of inflammatory bowel disease. World J Gastroenterol WJG. 2014;20(37):13501\u201311.","journal-title":"World J Gastroenterol WJG"},{"issue":"3","key":"1022_CR9","doi-asserted-by":"publisher","first-page":"100018","DOI":"10.1016\/j.chpulm.2023.100018","volume":"1","author":"S Ghosh","year":"2023","unstructured":"Ghosh S, Deshwal H, Haraf R, Raju S, Saeedan MB, Sarkar P, et al. Pulmonary Manifestations of Inflammatory Bowel Disease and Treatment Strategies. CHEST Pulm. 2023;1(3):100018.","journal-title":"CHEST Pulm"},{"key":"1022_CR10","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2174\/1874306401206010063","volume":"6","author":"M Schwaiblmair","year":"2012","unstructured":"Schwaiblmair M, Behr W, Haeckel T, M\u00e4rkl B, Foerg W, Berghaus TM. Drug-induced interstitial lung disease. Open Respir Med J. 2012;6:63\u201374. PMID: 22368587.","journal-title":"Open Respir Med J"},{"issue":"3","key":"1022_CR11","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.crohns.2009.03.007","volume":"3","author":"N Pedersen","year":"2009","unstructured":"Pedersen N, Duricova D, Munkholm P. Pulmonary Crohn\u2019s disease: a rare extra-intestinal manifestation treated with infliximab. J Crohn\u2019s Colitis. 2009;3(3):207\u201311.","journal-title":"J Crohn\u2019s Colitis"},{"issue":"5","key":"1022_CR12","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.arcped.2016.02.021","volume":"23","author":"S Abi-Khalil","year":"2016","unstructured":"Abi-Khalil S, Fadel N, Menassa-Moussa L, Torbey P, Haddad-Zebouni S. Spontaneous resolution of cryptogenic organizing pneumonia in pediatrics: a case report. Archiv Pediatr. 2016;23(5):519\u201322.","journal-title":"Archiv Pediatr"},{"issue":"6","key":"1022_CR13","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.hrtlng.2013.07.005","volume":"42","author":"S Kakavas","year":"2013","unstructured":"Kakavas S, Balis E, Lazarou V, Kouvela M, Tatsis G. Respiratory failure due to infliximab induced interstitial lung disease. Heart Lung. 2013;42(6):480\u20132.","journal-title":"Heart Lung"},{"issue":"Abstracts","key":"1022_CR14","doi-asserted-by":"publisher","first-page":"A6019","DOI":"10.1164\/ajrccm.2025.211.Abstracts.A6019","volume":"211","author":"G Marchi","year":"2025","unstructured":"Marchi G, Guglielmi G, Gabbrielli L, Pistelli F, Carrozzi L. Burden Beyond the Bowel: An Insightful Case of Severe Pneumonia in a Patient with Ulcerative Colitis on Infliximab Therapy. Am J Respir Crit Care Med. 2025;211(Abstracts):A6019\u20139.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"1022_CR15","doi-asserted-by":"publisher","first-page":"S1197","DOI":"10.14309\/01.ajg.0000711096.85866.5f","volume":"115","author":"J Sels","year":"2020","unstructured":"Sels J, Giang J, Ruzkowski C, Wisser K, Goff J. S2262 a rare manifestation of cryptogenic organizing pneumonia in a patient with ulcerative colitis being treated with an anti-TNF biosimilar. Am J Gastroenterol. 2020;115(1):S1197\u20137.","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"1022_CR16","doi-asserted-by":"publisher","first-page":"A1799","DOI":"10.1016\/j.chest.2022.08.1499","volume":"162","author":"P Lavere","year":"2022","unstructured":"Lavere P, Hotze TE. A case of secondary organizing pneumonia from infliximab. Chest. 2022;162(4):A1799\u20139.","journal-title":"Chest"},{"key":"1022_CR17","first-page":"A1597","volume":"193","author":"M Mauro","year":"2016","unstructured":"Mauro M, Yellappa N, Harbuz-Miller I, Markley D. Cryptogenic organizing pneumonia in a patient with Crohn\u2019s disease on infliximab- an extra intestinal pulmonary manifestation or drug induced complication? Am J Respir Crit Care Med. 2016;193:A1597.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"1022_CR18","doi-asserted-by":"publisher","first-page":"A4722","DOI":"10.1016\/j.chest.2023.07.3060","volume":"164","author":"L Albusoul","year":"2023","unstructured":"Albusoul L, Kassab C, ABU SAYF A. Infliximab-induced organizing pneumonia in a patient with ulcerative colitis. Chest. 2023;164(4):A4722\u20133.","journal-title":"Chest"},{"issue":"4","key":"1022_CR19","doi-asserted-by":"publisher","first-page":"A1390","DOI":"10.1016\/j.chest.2023.07.970","volume":"164","author":"V Sharma","year":"2023","unstructured":"Sharma V, Freeman H, O\u2019Sullivan M. A case of cryptogenic organizing pneumonia: ulcerative colitis or infliximab? Chest. 2023;164(4):A1390\u20130.","journal-title":"Chest"},{"issue":"10","key":"1022_CR20","doi-asserted-by":"publisher","first-page":"e01855","DOI":"10.14309\/crj.0000000000001855","volume":"12","author":"K Pham","year":"2025","unstructured":"Pham K, Wysham N. Infliximab-induced organizing pneumonia resulting in persistent respiratory impairment. ACG Case Rep J. 2025;12(10):e01855\u20135.","journal-title":"ACG Case Rep J"},{"issue":"2","key":"1022_CR21","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239\u201345. PMID: 7249508.","journal-title":"Clin Pharmacol Ther"}],"container-title":["Allergy, Asthma &amp; Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13223-026-01022-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-026-01022-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-026-01022-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T02:15:17Z","timestamp":1776824117000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13223-026-01022-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,14]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1022"],"URL":"https:\/\/doi.org\/10.1186\/s13223-026-01022-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7577704\/v1","asserted-by":"object"}]},"ISSN":["1710-1492"],"issn-type":[{"value":"1710-1492","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,14]]},"assertion":[{"value":"10 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication of clinical details and images was obtained from the patient\u2019s legal guardian.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22"}}